Cambridge Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Cambridge Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$197K	Sell	471 -120	-20%	-$50.7K	0.01%	265
2023 Q4	$240K	Buy	591 +3	+0.5%	+$1.11K	0.01%	246
2023 Q3	$204K	Sell	588 -1	-0.2%	-$350	0.01%	258
2023 Q2	$207K	Buy	589 +150	+34%	+$50.5K	0.01%	268
2023 Q1	$138K	Hold	439	–	–	0.01%	318
2022 Q4	$127K	Sell	439 -4	-0.9%	-$1.22K	0.01%	334
2022 Q3	$128K	Buy	443 +74	+20%	+$21.3K	0.01%	328
2022 Q2	$104K	Sell	369 -118	-24%	-$31.6K	﹤0.01%	383
2022 Q1	$127K	Sell	487 -95	-16%	-$22.5K	﹤0.01%	389
2021 Q4	$128K	Buy	+582	New	+$113K	﹤0.01%	394

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cambridge Trust's VRTX Position: Q1 2024 in Review

Cambridge Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2024, selling an estimated $50.7K and leaving 471 shares worth $197K. The position accounts for 0.01% of the portfolio, ranked #265.

Cambridge Trust first reported a position in VRTX in Q4 2021 and has held it in 10 quarters since. The position peaked at $240K in Q4 2023. 1,495 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Cambridge Trust held 471 shares of Vertex Pharmaceuticals worth $197K as of Q1 2024.
Cambridge Trust sold 120 Vertex Pharmaceuticals shares in Q1 2024, an estimated $50.7K.
Vertex Pharmaceuticals made up 0.01% of Cambridge Trust's portfolio in Q1 2024, its #265 holding.
Cambridge Trust first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Cambridge Trust's Vertex Pharmaceuticals position peaked at $240K in Q4 2023.
1,495 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.